| 產(chǎn)品名稱 | Linagliptin - BI 1356 |
| 產(chǎn)品貨號(hào) | Axon 2354 CAS [668270-12-0] MF C25H28N8O2MW 472.54 Purity: 99% Optical purity: Optically pure Soluble in DMSO Description Competitive and highly selective dipeptidyl peptidase (DPP)-4 inhibitor (IC50 value ca. 1 nM in vitro) with superior potency and long duration of action in vivo. Linagliptin is ≥10,000-fold more selective for DPP-4 than DPP-8, DPP-9, amino-peptidases N and P, prolyloligopeptidase, trypsin, plasmin, and thrombin and is 90-fold more selective than for fibroblast activation protein in vitro. Approved drug for treatment of type 2 diabetes with long-lasting effects on glucose tolerance through control of GLP-1 and insulin. References Certificates Categories Extra info J. Rungby. Inhibition of dipeptidyl peptidase 4 by BI-1356, a new drug for the treatment of beta-cell failure in type 2 diabetes. Exp.Opin. Investig. Drugs. 2009, 18, 835-838. ? L. Thomas et al. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor,…. J. Pharmacol. Exp. Ther. 2008, 325, 175-182. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology Diabetes & Metabolism DPP4 EC 3.4.14.5 Competitive and highly selective dipeptidyl peptidase (DPP)-4 inhibitor Chemical name (R)-8-(3-aminopiperidin-1-yl)-7-(but-2-ynyl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione Parent CAS No. [668270-12-0] Order Size Unit Price Stock 10 mg €90.00 In Stock |
| 產(chǎn)品價(jià)格 | 現(xiàn)貨詢價(jià)，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
Linagliptin - BI 1356Axon 2354 CAS [668270-12-0] MF C25H28N8O2
DescriptionCompetitive and highly selective dipeptidyl peptidase (DPP)-4 inhibitor (IC50 value ca. 1 nM in vitro) with superior potency and long duration of action in vivo. Linagliptin is ≥10,000-fold more selective for DPP-4 than DPP-8, DPP-9, amino-peptidases N and P, prolyloligopeptidase, trypsin, plasmin, and thrombin and is 90-fold more selective than for fibroblast activation protein in vitro. Approved drug for treatment of type 2 diabetes with long-lasting effects on glucose tolerance through control of GLP-1 and insulin.
Competitive and highly selective dipeptidyl peptidase (DPP)-4 inhibitor
Chemical name(R)-8-(3-aminopiperidin-1-yl)-7-(but-2-ynyl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione Parent CAS No.[668270-12-0] |
| 產(chǎn)品資料 |
